ClinicalTrials.gg
CompletedNCT05245422Updated Jun 18, 2025

Acceptance of a Partially Hydrolyzed Formula

An interventional study of Infant Formula - Partially hydrolyzed protein and Infant Formula - Intact protein in Fussy Infant (Baby), sponsored by Mead Johnson Nutrition. Completed at 11 sites in United States. Open to participants aged 15 Days to 75 Days. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Mead Johnson Nutrition (part of Reckitt) · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
15 Days to 75 Days
Sex
All
01

Study summary

A multi-center, double-blind, controlled, parallel-designed, prospective trial intended to evaluate the nutritive effects of a partially hydrolyzed cow's milk protein infant formula on infant fussiness.

Read the detailed description

A multi-center, double-blind, controlled, parallel-designed, prospective trial intended to evaluate the nutritive effects of a partially hydrolyzed cow's milk protein (PHP) infant formula on infant fussiness. Formula tolerance and intake, sleep characteristics, stool characteristics, parental quality of life, and medically confirmed adverse events will be compared between i two study groups.

02

Conditions studied

  • Fussy Infant (Baby)
03

In context

Lead sponsor

Mead Johnson Nutrition is the lead sponsor of 58 studies on the registry; 1 is open to participants now.

First submitted after Mead Johnson Nutrition became part of Reckitt.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Days to 75 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary caregiver has reliable access to the internet and a reliable device (such as a computer, tablet, or smartphone) to access mobile apps and be able to view and complete study questionnaires
  • Singleton birth
  • 15 to 75 days of age at Visit 1, inclusive (day of birth is considered Day 0)
  • Gestational age of ≥37 to 42 weeks (36 weeks and six days is considered 36 weeks' gestational age)
  • Birth weight of 2500 g (5 lbs 8 oz) or more
  • Exclusively receiving an intact protein infant formula (cow's milk-based or plant-based) for 7 days prior to Visit 1
  • Answer to question: "On average, how fussy has your baby been over the past 3 days" is moderately fussy, very fussy, or extremely fussy at Visit 1
  • Parent(s) or legal guardian has full intention to exclusively feed study formula during the study period
  • Parent(s) or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study
  • Signed obtained from parent or legal guardian for infant's participation in the study
  • Signed authorization obtained from parent or legal guardian to use and/or disclose Protected Health Information for infant from birth through the length of the study period

Exclusion criteria

Exclusion Criteria:

  • Infant has been weighed by a health care professional (HCP) and is identified with inadequate weight gain or failure-to-thrive
  • Diagnosis or suspicion of cow's milk protein allergy by a healthcare professional
  • Any acute illness within the 3 days prior to Visit 1
  • Infant has had immunizations or a surgical procedure within the 3 days prior to or on Visit 1
  • Immunizations are planned for the infant during any of the 7 days after Visit 1
  • Use of oral, intramuscular or intravenous antibiotics within the 7 days prior to Visit 1
  • Infant has had bloody stools (visible to the naked eye) within the 7 days prior to Visit 1
  • Infant has been taking medication (prescribed and over-the-counter) for gastrointestinal conditions for any of the 7 days prior to Visit 1 (however, probiotics are allowed)
  • Infant has a surgical procedure planned during the study period
  • History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
  • History of underlying neurological or organic disease likely to cause fussiness, such as (but not limited to) a doctor's diagnosis of neonatal abstinence syndrome and inflammatory or orthopedic disorders
  • Infant is (according to a doctor's diagnosis of immunodeficiency such as combined immunodeficiencies, DiGeorge syndrome, Wiskott-Aldrich syndrome, severe congenital neutropenia and secondary immunodeficiencies linked to infection, Down syndrome or others)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Active comparator
    Cow's milk intact protein infant formula

    Control

    Other: Infant Formula - Intact protein

  • Experimental
    Partially hydrolyzed cow's milk protein infant formula

    Investigational

    Other: Infant Formula - Partially hydrolyzed protein

Interventions

  • OtherInfant Formula - Partially hydrolyzed protein

    Partially hydrolyzed cow's milk protein

  • OtherInfant Formula - Intact protein

    Intact cow's milk protein

06

What researchers measure

Primary outcomes

  1. Fussiness

    Daily Diary

    Time frame: Study Feeding Days 1 through 7

Secondary outcomes

  1. Fussiness

    Daily Diary

    Time frame: Study Feeding Days 8-28

  2. Gassiness

    Daily Diary

    Time frame: Study Feeding Days 1-28

  3. Crying

    Daily Diary

    Time frame: Study Feeding Days 1-28

  4. Spit-up

    Daily Diary

    Time frame: Study Feeding Days 1-28

  5. Sleep

    Daily Diary

    Time frame: Study Feeding Days 1-28

  6. Stool frequency

    Daily Diary

    Time frame: Study Feeding Days 1-28

  7. Stool consistency

    Daily Diary

    Time frame: Study Feeding Days 1-28

  8. Study Formula Intake

    24-hour Recall of Study Formula Intake

    Time frame: Study Feeding Day 7 and Study Feeding Day 25 (+3 days)

  9. Brief Infant Sleep Questionnaire

    Revised Short Form (BISQ-R SF)

    Time frame: Study Feeding Day 14 (+2 days) and Study Feeding Day 25 (+ 3 days)

  10. Quality of Life Questionnaire

    Pediatric Quality of Life Inventory™ Family Impact Module (PedsQL FIM)-Acute

    Time frame: Study Feeding Day 7 (+2 days) and Study Feeding Day 25 (+3 days)

  11. Medically confirmed adverse events

    Collected from medical records

    Time frame: Day 1 through end of feeding

07

Study locations

11 sites
  • Birmingham Pediatric Associates
    Birmingham, Alabama 35205, United States
  • Alabama Clinical Therapeutics
    Birmingham, Alabama 35235, United States
  • DBC Research USA
    Miramar, Florida 33025, United States
  • Proactive Clinical Research
    Sarasota, Florida 34243, United States
  • Mid Valley Research Inc.
    Moline, Illinois 61265, United States
  • Frontier Pediatric Research
    Lincoln, Nebraska 68502, United States
  • Meridian Clinical Research
    Charleston, South Carolina 29414, United States
  • Tribe Clinical Research
    Greenville, South Carolina 29607, United States
  • AVIATI Healthcare & Clinical Research
    Memphis, Tennessee 38115, United States
  • South Texas Pediatric Research Group
    Del Rio, Texas 78840, United States
  • Proactive Clinical Research
    Edinburg, Texas 78539, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jul 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2022
First posted
Feb 18, 2022
StartActual
Feb 28, 2022
Primary completionActual
Jul 14, 2023
CompletionActual
Jul 14, 2023
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245422
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Feb 28, 2022
Primary completion
Jul 14, 2023
Completion
Jul 14, 2023
Last update
Jun 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion